Rx Rundown: Bristol Myers Squibb, J&J, Pfizer and more
Check out a roundup of this week’s medical marketing news, executives on the move and industry chatter.
Source: mmm-online.com
Peter Lebowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Lebowitz Today - Breaking & Trending Today
Amivantamab With Lazertinib Can Reduce Risk of Disease Progression By 30% in Patients With NSCLC
Compared to osimertinib alone, first-line treatment with amivantamab plus lazertinib was also shown to improve progression-free survival and have an increased duration of response.
Source: pharmacytimes.com
Johnson & Johnson : Janssen Aims to Define New Standards of Care in the Treatment of Solid Tumor Cancers with Transformative Data Planned for Presentation at ESMO -October 16, 2023 at 08:33 am EDT
News Release Media Contacts: Brian Kenney +1 215-620-0111 Suzanne Frost +1...
Source: marketscreener.com
Topline Data Demonstrate Survival Improvement With Amivantamab-vmjw for NSCLC
The MARIPOSA study evaluated amivantamab-vmjw (Rybrevant; Janssen Pharmaceutical) in combination with lazertinib compared to osimertinib and compared to lazertinib monotherapy in the first-line treatment of EGFR-mutated non–small cell lung cancer.
Source: pharmacytimes.com
First-Line Amivantamab Plus Lazertinib Meets PFS End Point in EGFR+ NSCLC
First-line treatment with the combination of amivantamab and lazertinib resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with osimertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR mutations.
Source: onclive.com